Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile

Author(s): Silvio Danese*, Gionata Fiorino.

Journal Name: Current Medicinal Chemistry

Volume 26 , Issue 2 , 2019

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer


Biosimilars of infliximab (CT-P13) are currently approved and available for the same indications as for the originator. Some concerns about safety and immunogenicity have risen in the past because of lack of data in IBD. Since 2015, several cohort studies have been conducted in IBD showing that CT-P13 has comparable safety and efficacy profile to the originator, both in adult and pediatric population, either in naïve patients or even in those who switched from the originator to CT-P13. This review aims to analyze the current literature data in order to define a clear patient profile, to identify those IBD patients who would benefit the most from the use of CT-P13.

Keywords: Infliximab, biosimilar, CT-P13, inflammatory bowel disease, Crohn’s disease, ulcerative colitis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Page: [280 - 287]
Pages: 8
DOI: 10.2174/0929867325666180514100204
Price: $58

Article Metrics

PDF: 28
PRC: 1